Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
Clinical Trial
[키워드] Abstract
Adverse reaction
age
All participant
analysed
Analysis
assigned
assist
BBIBP-CorV
Beijing
Block randomisation
cause
center
children
China
Chinese
city
Cohort
Control
control group
COVID-19
COVID-19 vaccine
creation
District
dose
doses
double-blind
drug
Efficacy
eight
elicited
eligible participant
Fever
geometric
GMT
group
healthy
Humoral response
inactivated
individual
Infectious diseases
information
injection
Major
material
Mild
moderate
neutralising antibody
New
Pain
pandemic
participant
phase 3 trial
plan
prevention
Primary outcome
Program
randomised
Randomly
ranged
receive
regimen
Registered
robust
Safe
Safety
SARS-CoV infection
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 transmission
Science
screened
secondary outcome
severity
Shangqiu
stratified
Support
Symptom
technology
tested
the SARS-CoV-2 virus
titre
translation
Trial
vaccination
Vaccine
was done
were excluded
[DOI] 10.1016/S1473-3099(21)00462-X PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S1473-3099(21)00462-X PMC 바로가기 [Article Type] Clinical Trial